<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03672188</url>
  </required_header>
  <id_info>
    <org_study_id>VIR-2218-1001</org_study_id>
    <nct_id>NCT03672188</nct_id>
  </id_info>
  <brief_title>Study of VIR-2218 in Healthy Volunteers and Patients With Chronic Hepatitis B</brief_title>
  <official_title>A Phase 1/2, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of VIR-2218</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vir Biotechnology, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Alnylam Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Vir Biotechnology, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1/2 study in which healthy volunteers and subjects with chronic HBV infection
      will receive VIR-2218 or placebo and will be assessed for safety, tolerability,
      pharmacokinetics, and antiviral activity (only in subjects with chronic HBV).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 14, 2018</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects with Adverse Events as assessed by CTCAE v5.0</measure>
    <time_frame>Up to 364 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with abnormalities in vital signs, electrocardiogram (ECG), and clinically significant laboratory findings</measure>
    <time_frame>Up to 112 days post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK: maximum plasma concentration (ng/mL)</measure>
    <time_frame>Up to 7 days post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: time to reach maximum plasma concentration (h)</measure>
    <time_frame>Up to 7 days post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: area under the plasma concentration versus time curve (ng*h/mL)</measure>
    <time_frame>Up to 7 days post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: percent of area extrapolated from AUC last to infinity (%)</measure>
    <time_frame>Up to 7 days post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: apparent terminal elimination half-life (h)</measure>
    <time_frame>Up to 7 days post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: apparent plasma clearance (L/h)</measure>
    <time_frame>Up to 7 days post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: apparent volume of distribution (L)</measure>
    <time_frame>Up to 7 days post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK (healthy volunteers): fraction eliminated in the urine (mg)</measure>
    <time_frame>Up to 7 days post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK (healthy volunteers): renal clearance (L/h)</measure>
    <time_frame>Up to 7 days post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CHB: Maximum reduction of serum HBsAg from baseline</measure>
    <time_frame>Up to 336 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CHB: Number of subjects with serum HBsAg loss at any time point</measure>
    <time_frame>Up to 336 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CHB: Number of subjects with sustained serum HBsAg loss for &gt;/= 6 months</measure>
    <time_frame>Up to 336 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CHB: Number of subjects with anti-HBs seroconversion at any timepoint</measure>
    <time_frame>Up to 336 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CHB: Number of subjects with HBeAg loss and/or anti-HBe seroconversion at any timepoint</measure>
    <time_frame>Up to 336 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">104</enrollment>
  <condition>Chronic Hepatitis B</condition>
  <arm_group>
    <arm_group_label>VIR-2218</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VIR-2218</intervention_name>
    <description>VIR-2218 given by subcutaneous injection</description>
    <arm_group_label>VIR-2218</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Sterile normal saline (0.9% NaCl) given by subcutaneous injection</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Healthy Volunteers:

        Inclusion Criteria:

          -  Male or female age 18 - 55

          -  BMI 18 - 32 kg/m^2

        Exclusion Criteria:

          -  Any clinically significant chronic or acute medical condition that makes the volunteer
             unsuitable for participation

          -  History or evidence of drug or alcohol abuse

          -  History of intolerance to SC injection

        CHB Patients:

        Inclusion Criteria:

          -  Male or female age 18 - 65

          -  BMI 18 - 32 kg/m^2

          -  Chronic HBV infection for &gt;/= 6 months

        Exclusion Criteria:

          -  Any clinically significant chronic or acute medical condition that makes the volunteer
             unsuitable for participation

          -  Significant fibrosis or cirrhosis

          -  History or evidence of drug or alcohol abuse

          -  History of intolerance to SC injection

          -  History of chronic liver disease from any cause other than chronic HBV infection

          -  History of hepatic decompensation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Birtinya</city>
        <state>Queensland</state>
        <zip>4575</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Fitzroy</city>
        <state>Victoria</state>
        <zip>3065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Busan</city>
        <zip>49241</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Auckland</city>
        <zip>1010</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Auckland</city>
        <zip>2025</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Hat Yai</city>
        <zip>90110</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Khon Kaen</city>
        <zip>40002</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Hong Kong</country>
    <country>Korea, Republic of</country>
    <country>New Zealand</country>
    <country>Thailand</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>September 11, 2018</study_first_submitted>
  <study_first_submitted_qc>September 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 14, 2018</study_first_posted>
  <last_update_submitted>May 29, 2020</last_update_submitted>
  <last_update_submitted_qc>May 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis B Virus</keyword>
  <keyword>Chronic Hepatitis B</keyword>
  <keyword>HBV</keyword>
  <keyword>Hepatitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

